Clinical Trial

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 30, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of the trial is to test the hypothesis that the benefit of denosumab is maintained if administered only every 12 weeks as compared to every 4 weeks.
Protocol Amendment History 48 amendments
This ClinicalTrials.gov record has been amended 48 times since 2014-01-29; most recent amendment 2025-12-23.
Status change: Recruiting → Active, Not Recruiting 2024-03-20
Status change: Active, Not Recruiting → Recruiting 2021-12-06
Status change: Recruiting → Active, Not Recruiting 2021-01-12
Status change: Not Yet Recruiting → Recruiting 2014-07-17
Trial Details
NCT Number NCT02051218
Lead Sponsor Swiss Cancer Institute
Conditions Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases
Enrollment 1,380 participants
Start Date 2014-07-16
Primary Completion 2026-06-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-30